Highlights of This Issue 2593

SPECIAL FEATURES

CCR Translations

2595 Oncolytic Virotherapy Needs Trials, Not Access Programs
Kevin J. Harrington
See article, p. 2734

Molecular Pathways

2598 Molecular Pathways: Tumor-Derived Microvesicles and Their Interactions with Immune Cells In Vivo
Ferdinando Pucci and Mikael J. Pittet

CCR Focus

2606 PFS: The Endpoint We Love and Love to Hate
Susan E. Bates

2607 Overview: Progression-Free Survival as an Endpoint in Clinical Trials with Solid Tumors
Ronald L. Korn and John J. Crowley

2613 Missing Data and Measurement Variability in Assessing Progression-Free Survival Endpoint in Randomized Clinical Trials
Rajeshwari Sridhara, Sumithra J. Mandrekar, and Lori E. Dodd

2621 The Imaging Viewpoint: How Imaging Affects Determination of Progression-Free Survival
Daniel Carl Sullivan, Lawrence H. Schwartz, and Binsheng Zhao

CANCER THERAPY: PRECLINICAL

2629 The Clinical Viewpoint: Definitions, Limitations of RECIST, Practical Considerations of Measurement
Liza C. Villaruz and Mark A. Socinski

2637 Assessment of Audit Methodologies for Bias Evaluation of Tumor Progression in Oncology Clinical Trials
Jenny J. Zhang, Lijun Zhang, Huanyu Chen, Anthony J. Murgo, Lori E. Dodd, Richard Pazdur, and Rajeshwari Sridhara

Modeling the Relationship between Progression-Free Survival and Overall Survival: The Phase II/III Trial
Mary W. Redman, Bryan H. Goldman, Michael LeBlanc, Anne Schott, and Laurence H. Baker

Aberrant BAF57 Signaling Facilitates Prometastatic Phenotypes
Sucharitai Balasubramanian, Clay E.S. Comstock, Adam Ertel, Kwang Won Jeong, Michael R. Stalculp, Sankar Addya, Peter A. McCue, William F. Ostrander Jr, Michael A. Augello, and Karen E. Knudsen

Relapsed Classic E-Cadherin (CDH1)–Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 (ERBB2) Gene Mutations

Potent Antimyeloma Activity of a Novel ERK5/CDK Inhibitor
Stela Álvarez-Fernández, Maria Jesús Ortiz-Ruiz, Tracy Parrott, Sara Zaknoen, Enrique M. Ocio, Jesús San Miguel, Francis J. Burrows, Azucena Esparís-Ogando, and Atanasio Pandiella

Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAFV600E Colorectal Cancer

Contents

The Journal of Clinical and Translational Research May 15, 2013 • Volume 19 • Number 10

The Journal of Clinical and Translational Research iii www.aacrjournals.org

Downloaded from clincancerres.aacrjournals.org on April 29, 2017. © 2013 American Association for Cancer Research.
Temozolomide-Mediated DNA Methylation in Human Myeloid Precursor Cells: Differential Involvement of Intrinsic and Extrinsic Apoptotic Pathways

Inhibition of Melanoma Growth by Small Molecules That Promote the Mitochondrial Localization of ATF2
Tal Varsano, Eric Lau, Yongmei Feng, Marine Garrido, Loribelle Milan, Susanne Heynen-Genel, Christian A. Hassig, and Ze'e v A. Ronai

Identification of Prognosis-Relevant Subgroups in Patients with Chemoresistant Triple-Negative Breast Cancer
Ke-Da Yu, Rui Zhu, Ming Zhan, Angel A. Rodriguez, Wei Yang, Stephen Wong, Andreas Makris, Brian D. Lehmann, Xi Chen, Ingrid Mayer, Jennifer A. Pietenpol, Zhi-Ming Shao, W. Fraser Symmans, and Jenny C. Chang

Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
Anna Kanerva, Petri Nokisalmi, Iulia Diaconu, Anna-Kaisa Koski, Vincenzo Cerullo, Ilkka Liikanen, Siri Tahtinen, Minna Oksanen, Raita Heiskanen, Salla Pesonen, Tiina Joensuu, Tuomo Alanko, Kaarina Partanen, Leena Laasonen, Kalevi Kairemo, Sari Pesonen, Lotta Kangasniemi, and Akseli Hemminki

Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance

Correction: Chromosome 5q Loss in Colorectal Flat Adenomas
ABOUT THE COVER

This image is taken from a bone metastasis in a patient with stage IV relapsed invasive CDH1 mutated lobular carcinoma of the breast. The tumor was negative for \textit{ERBB2 (HER2)} amplification (FISH). The targeted next generation sequencing assay used in this study found an \textit{ERBB2-GRB7} putative gene fusion that has not been previously reported. The fusion retains the kinase domain of \textit{ERBB2} (uniprot.org) which suggests that it could result in \textit{ERBB2} activation. The 17q12-21 amplicon which includes both \textit{ERBB2} and \textit{GRB7} is frequently amplified in breast cancer and preclinical studies suggest that it may be a recombination hotspot. An expression screening study has reported that \textit{GRB7} can function as an \textit{ERBB2}-dependent oncogene. \textit{GRB7} encodes an adaptor protein that interacts with \textit{ERBB2} and has been shown in a preclinical study to enhance its transformative capacity and increase \textit{ERBB2} phosphorylation in fibroblasts. For details, see the article by Ross and colleagues on page 2668 of this issue.

AC icon indicates Author Choice

CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org

For more information please visit www.aacrjournals.org